Keywords
Alzheimer’s Disease, Food Intake, Dementia, Macronutrients, Vitamins, Cognition
Alzheimer’s Disease, Food Intake, Dementia, Macronutrients, Vitamins, Cognition
Alzheimer's disease (AD) is the most common type of dementia, characterized by cognitive and neuropsychiatric manifestations that result in progressive disability1,2. Several factors contribute to the neurodegenerative process of AD. Lack of availability of certain nutrients, abnormal protein processing and neuronal membrane degeneration accelerate dysfunction and synaptic loss from the onset of disease3.
The medial temporal lobe is an area of the brain that is involved in the regulation of food intake4, and a site where neurodegeneration is typically present5. The behavioral modification of the AD patient interferes directly with the reduction of food consumption and the absorption of essential nutrients for the normal functioning of the body6.
The synthesis of synaptic membranes is dependent on various nutrients, such as folate, vitamin B12, vitamin B6, vitamin E, vitamin C and selenium. Inadequate ingestion and metabolism of these nutrients is related to increased phospholipid degradation and degeneration of neuronal membranes responsible for synapse loss3.
The nutritional status and food intake in the elderly differ by their cognitive, physical and biological capabilities. Taste reduction, difficulty in swallowing and xerostomia may be the result of neuropathological disorders, senility, or even induced by polypharmacy due to a higher incidence of chronic diseases resulting in them being more likely to be taking a combination of pharmaceuticals7,8.
Since the nutritional status directly affects the patient's physiological condition, causing the elderly to be more susceptible to decreased biological function, making them more susceptible to falls, fractures, protein-energy malnutrition, and associated nutritional deficiencies6, this study had the intention of analyze the food intake in patients with AD, comparing it with the control group, identifying micro and macronutrient deficits that lead to worsening dementia and decreased quality of life.
This study was approved by the Ethics Committee of the State University of Midwest (UNICENTRO) under number 026/2011. Patients and their caregivers received information on the purpose, methods, risks and benefits of research and gave written informed consent to participate in the study. Patients with any nutritional changes were referred to the Nutrition School Clinic of UNICENTRO for follow-up.
A cross-sectional study with a control group was performed, with 37 elderly controls and 32 AD patients.
The elderly were attended and diagnosed clinically with AD in the health centers through the Unified Health System (SUS) and were passed through a confirmed diagnosis issued by a geriatric doctor or neurologist, and assisted by the Association of Studies, Research and Assistance to People with Alzheimer's (AEPAPA) in Guarapuava, Paraná.
The control group, in turn, was formed by healthy elderly participants of exercise groups and cultural activities for seniors, provided by the Social Welfare Department of the city of Guarapuava. A Mini-Mental State Examination (MMSE) was performed and evaluated by a trained healthy professional, applied to the health elderly as exclusion criteria for the control group. Also, they agreed in participate of the study and gave written informed consent in participate in the study.
Patients and elderly without AD not found in their homes on three attempted visits on different days of the week, those who died, the residents of the countryside, and those who had moved to other cities, in addition to those unwilling or who rejected the survey after the first visit, along with those who did not agree with the terms of the Free and Informed Consent Term (TCLE) were excluded from the study.
The study occurred between August 2013 to June 2014, with an initial sample of 55 AD patients attending SUS in Guarapuava, and after applying the exclusion criteria, the sample consisted of 32 patients. The sample of healthy elderly was initially 50 participants, of which 13 declined to continue due to the amount of data that needed to collected and the time it would take to collect this data, consisting of 37 patients. All remaining individuals after applying exclusion criteria completed the study.
To evaluate the nutritional status, anthropometric measurements were collected: weight (kg), height (m), body mass index - BMI (kg/m2). Weight and height were collected according to the methods recommended by the Food and Nutrition Surveillance System - SISVAN9. When weighing and stature measurement was not possible due to the patient's health conditions, weight and height were estimated using theoretical formulas, using arm circumference (AC) and calf circumference (CC) measures, knee height and subscapular cutaneous fold. The formulae used to estimate weight were:
a) For men: weight = {[1.73 × Arm Circumference (cm)] + [0.98 × Calf Circumference (cm)] + [0.37 × subscapular skin fold (mm)] + [1,16 × Knee Height (cm)] = 81.69;
b) For women: weight = {[0.98 × Arm Circumference (cm)] + [1.27 × Calf Circumference (cm)] + [0.4 × subscapular skin fold (mm)] + [0.87 × Knee Height (cm)] = 62.35}.
The formulae used for height estimation (m) in the elderly were:
a) For males: height = {64,19 - [0,04 × age (years)] + [2,02 × knee height (cm)]};
b) For women: height = {84,88 - [0,24 × age (years)] + [1,83 × knee height (cm)]}.
By three-day and 24-hour dietary recall, the caregiver noted in forms all food and drink consumed (Forms are available as part of Dataset 110)). The collected information was used to perform a diet analysis including values of energy, macronutrients and micronutrients provided by DietWin® software, version 2008.
All values obtained from the average of four days of each nutrient were compared with the recommendations of the Dietary Reference Intakes (DRIs), according to the gender and age of the patient. As yet there are no specific recommendations for AD patients.
Evaluated consumption in grams (g), milligrams (mg) and micrograms (mcg) of nutrients, and calculated the percentage of adequacy by the following formula: adjustment percentage = amount of ingested nutrient (g/mg/mcg)/DRI recommendation (g/mg/mcg) × 100.
The elderly were evaluated through the Mini Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) between August 2013 to June 2014. Each category is classified based on scores - none/questionable dementia, mild dementia, moderate or severe11. The CDR and MMSE was applied and evaluated by a trained health professional.
Data were analyzed using the SPSS 20.0 statistical software for Windows, presented as median and interquartile range, relative and absolute frequency. Prior to the analysis, the following assumptions were tested on the numerical variables: homogeneity of the variances using the Levene test, and distribution of the data using the Shapiro-Wilk test. If the assumptions were incorrect data was analyzed using the Kruskal-Wallis test. When necessary, we used the multiple comparisons analysis with the Bonferroni level of significance correction. The Chi-square test, Fisher's Continuity Correction and Exact Correction were used to identify associations between the diagnosis of AD and clinical and sociodemographic variables. A significance level of p <0.05 was adopted.
In total, 69 participants took part in the study: 37 from the control group and 32 from the AD group.
Table 1 shows anthropometric characteristics of the sample, these data are characterizing this population according to CDR, age, current weight, height and BMI. Data are presented as median (P25-P75).
Guarapuava, PR, Brazil. 2013.
The age of the elderly ranged from 57 to 94 years, with a median of 74 years, with a median height of 1.58m of the total sample. Regarding body weight, the control group had the highest average, and the weight in AD patients decreased with increased severity of disease.
Regarding the sociodemographic characteristics (Table 2), 45 (65.2%) were female; 20 were married in the control group (29.0%) and in the AD group there were 7 (10.1%); 3 from the control group were unmarried (4.3%) and in the AD group there were 7 (10.0%). There were 13 widowers in the control group (18.8%), and 17 (24.5%) in the AD group.
Guarapuava, PR, Brazil. 2013.
The average family income reported by the participants in the control group was R$ (Brazilian real - BRL) 904.00 ± 8.99 (US$ 275.76) and the participants with the disease presented income around R$ 1.031.13 ± 67.29 (US$ 314.54).
Table 3 shows the comparison of carbohydrate intake. The consumption was lower in the control group but there was no difference between the groups of patients with dementia (p> 0.05). In contrast, with respect to the consumption of proteins, as disease progressed this concomitantly decreases. The only macronutrient that gave a significant difference (p <0.05) was the lipid values, in relation to the control group (113.64% adequacy), which presented a greater consumption than CDR-1, mild dementia (86.95% adequacy) and CDR-3, severe dementia (7751% adequacy).
Guarapuava, PR, Brazil. 2013.
CDR | |||||||
---|---|---|---|---|---|---|---|
Control | Mild | Moderate | Severe | p | Contrasts p<0.05 | ||
(n=37) | (n=6) | (n=10) | (n=16) | ||||
Energy consumption‡ | kcal | 1277.5 (1043.25-1626.25) | 1338.75 (1128.5-1991.25) | 1353.75 (1063.25-1795) | 1324.38 (1117.5-1467) | 0.976 | |
% | 64.95 (56.07-84.04) | 90.86 (59.31-123.39) | 86.07 (68.33-113.2) | 85.72 (67.84-106.07) | 0.070 | ||
Carbohydrates‡ | g | 156.37 (118.04-216) | 199.43 (161.43-282.46) | 218.81 (144.37-265) | 191.03 (164.21-223.05) | 0.163 | |
% | 50.82 (43.91-55.72) | 56.98 (53.22-58.35) | 62.56 (57.47-78.66) | 61.55 (50.78-68.54) | 0.298 | ||
Lipids* | g | 42.89 (31.79-56.27) | 35.13 (24.68-57.28) | 38.84 (28.63-47.7) | 32.24 (17.75-42.63) | 0.149 | |
% | 113.64 (94.61-122.28) | 86.95 (85.08-94.14) | 104.31 (71.43-146.83) | 77.51 (60.94-106.43) | 0.002 | Control >1;3 | |
Proteins‡ | g | 65.84 (48.45-76.21) | 61.4 (54.62-86.42) | 62.47 (53.71-79.55) | 51.07 (40.05-63.31) | 0.155 | |
% | 82.99 (68.63-98.99) | 104.36 (86.5-124.09) | 100.53 (64.37-148.45) | 79.89 (55.33-111.82) | 0.471 | ||
Cholesterol‡ | mg | 189 (142.51-232.85) | 162.76 (146.91-180.63) | 234.37 (176.58-277.95) | 167.83 (109.76-205.76) | 0.146 | |
% | 94.5 (71.26-116.42) | 81.38 (73.45-90.31) | 117.19 (88.29-138.97) | 83.91 (54.88-102.88) | 0.146 | ||
Omega 3‡ | g | 0.34 (0.22-0.45) | 0.23 (0.12-0.41) | 0.3 (0.23-0.53) | 0.26 (0.12-0.3) | 0.205 | |
% | 28.18 (19.55-37.27) | 14.06 (10.91-37.05) | 21.25 (14.38-32.97) | 21.44 (9.05-24.89) | 0.142 | ||
Omega 6‡ | g | 3.07 (1.94-4.71) | 1.89 (1.12-5.16) | 2.86 (2.65-5.62) | 2.21 (1.11-2.91) | 0.187 | |
% | 27.77 (15.86-42.82) | 15.15 (7.96-46.89) | 24.66 (15.91-40.63) | 18.09 (9.75-24.51) | 0.299 |
Data are presented as median (p25-P75) CDR: clinical dementia rating (cases); Kruskall-Waliss (Bonferroni for multiple comparisons). * There was a statistical difference between elderly control subjects and elderly with mild and advanced dementia (p<0.05). ‡There was no difference between groups (p>0.05).
Table 4 presents the data in relation to the intake of vitamins. For vitamin B1, the control group consumed a median 0.77 (0.55-0.97) mg on median, lower than that of CDR-2, which consumed a median of 1.27 (1.1-1.47) mg (p <0.05). For vitamin B3, differences were also observed: the median control group ingestion was 6.22 (4.85-8.68) mg. CDR-2 and CDR-3 patients had a significant higher (p <0.05) consumption (10.27 (8.8-14.05) and 11.22 (9.04-14.1) mg, respectively). Vitamin D, E, and K intake were higher in the control group when compared to all stages of dementia (vitamin D, p> 0.05; vitamin E, p> 0.05; vitamin K, p <0.05).
Among the minerals shown in Table 5, only calcium, chromium and iodine showed differences between the groups (p <0.05).
Guarapuava, PR, Brazil. 2013.
Control | mild | Moderate | Severe | P | Contrasts p<0.05 | ||
---|---|---|---|---|---|---|---|
(n=37) | (n=6) | (n=10) | (n=16) | ||||
Vitamin A‡ | mcg | 176.18 (75.89-274.95) | 97.14 (38.86-162.06) | 132.44 (24.98-250.54) | 123.82 (73.92-158.32) | 0.285 | |
% | 20.15 (9.99-34.57) | 11.73 (4.32-23.15) | 16.63 (3-27.84) | 15.99 (9.7-22.62) | 0.315 | ||
Vitamin B1** | mg | 0.77 (0.55-0.97) | 1.05 (0.77-1.28) | 1.27 (1.1-1.47) | 0.91 (0.68-1.36) | 0.025 | Control <2 |
% | 64.77 (49.55-87.95) | 87.5 (70-106.25) | 106.26 (98.96-133.86) | 78.92 (62.05-118.38) | 0.037 | Control <2 | |
Vitamin B2‡ | mg | 0.89 (0.53-1.24) | 0.83 (0.66-1.15) | 1.13 (0.53-1.51) | 1.36 (0.91-2.13) | 0.042 | Control <3 |
% | 75.45 (47.95-95) | 70.01 (50.96-88.46) | 97.6 (40.77-120.45) | 113.71 (77.36-177.88) | 0.042 | Control <3 | |
Vitamin B3*** | mg | 6.22 (4.85-8.68) | 8.67 (2.86-11.66) | 10.27 (8.8-14.05) | 11.2 (9.04-14.1) | 0.001 | Control <2;3 |
% | 44.45 (34.63-62) | 58.63 (17.86-72.88) | 73.36 (55-97.61) | 78.26 (60.61-94.88) | 0.002 | Control <2;3 | |
Vitamin B5‡ | mcg | 0.68 (0.3-1.58) | 0.12 (0.05-0.34) | 0.27 (0.07-0.36) | 0.33 (0.08-0.93) | 0.032 | Control >2 |
% | 13.65 (5.95-31.6) | 2.48 (0.95-6.85) | 3.93 (1.3-7.15) | 6.58 (1.65-18.65) | 0.027 | Control >2 | |
Vitamin B6‡ | mg | 0.6 (0.48-0.82) | 0.43 (0.25-0.57) | 0.55 (0.31-0.91) | 0.62 (0.41-0.85) | 0.362 | |
% | 35.94 (28.13-49) | 21.63 (12.38-35.78) | 39.25 (25.63-63.91) | 34.59 (23.05-53.05) | 0.253 | ||
Vitamin B12‡ | mg | 0.9 (0.08-1.58) | 0.12 (0-0.23) | 0.04 (0-0.65) | 0.2 (0-1.01) | 0.156 | |
% | 37.4 (3.23-65.94) | 4.84 (0-9.38) | 1.82 (0-26.88) | 8.33 (0-42.03) | 0.156 | ||
Vitamin C‡ | mg | 37.69 (21.57-62.9) | 75.32 (19.21-119.27) | 43.45 (30.26-65.27) | 60.67 (23.65-126.85) | 0.594 | |
% | 50.25 (28.76-83.86) | 93.97 (21.34-145.45) | 52.61 (33.62-87.02) | 75.82 (28.86-143.99) | 0.607 | ||
Vitamin D† | mcg | 0.21 (0.01-0.84) | 0 (0-0) | 0.04 (0-0.2) | 0.04 (0-0.25) | 0.010 | Control >1;2;3 |
% | 0.04 (0-0.14) | 0 (0-0) | 0.01 (0-0.03) | 0.01 (0-0.04) | 0.010 | Control >1;2;3 | |
Vitamin E† | mg | 3.44 (0.81-6.39) | 0.76 (0.35-1.01) | 0.84 (0.26-2.05) | 1.31 (0.26-3) | 0.009 | Control >1;2;3 |
% | 22.92 (5.37-42.62) | 5.08 (2.32-6.72) | 5.62 (1.73-13.67) | 8.7 (1.73-20) | 0.009 | Control >1;2;3 | |
Vitamin H‡ | mg | 4.85 (1.17-8.54) | 0.06 (0.03-0.09) | 2.32 (0.03-6.6) | 3.09 (0.07-8.81) | 0.108 | |
% | 16.17 (3.9-28.47) | 0.2 (0.08-0.28) | 7.73 (0.08-22) | 10.29 (0.25-29.36) | 0.108 | ||
Vitamin K† | mg | 0.06 (0.02-0.13) | 0.01 (0-0.02) | 0 (0-0.02) | 0.01 (0-0.02) | 0.002 | Control >1;2;3 |
% | 0.1 (0.02-0.19) | 0.01 (0-0.02) | 0.01 (0-0.05) | 0.02 (0-0.04) | 0.005 | Control >1;2;3 |
Data are presented as median (P25-P75). CDR: clinical dementia rating (cases); n; sample number; Kruskall-Waliss (Bonferroni for multiple comparisons). ** There was a statistical difference between elderly control subjects and elderly with moderate dementia (p<0.05). *** There was a statistical difference between elderly control subjects and elderly with mild and advanced dementia (p<0.05). † There was a statistical difference between elderly control subjects and elderly with mild, moderate and advanced dementia (p<0.05). ‡ There was no difference between groups (p>0.05).
Guarapuava, PR, Brazil. 2013.
CDR | |||||||
---|---|---|---|---|---|---|---|
Control | Mild | Moderate | Severe | p | Contrasts p<0,05 | ||
(n=37) | (n=6) | (n=10) | (n=16) | ||||
Calcium*** | mg | 299.63 (209.1-509.25) | 469.27 (344.57-640.71) | 559.66 (304.57-769.72) | 613.32 (410.31-789.35) | 0.003 | Control <2;3 |
% | 29.96 (20.91-50.93) | 46.93 (34.46-64.07) | 55.97 (30.46-76.97) | 61.33 (41.03-78.94) | 0.003 | Control <2;3 | |
Copper‡ | mg | 0.77 (0.53-1.03) | 0.91 (0.35-2.35) | 0.7 (0.55-1.29) | 0.75 (0.6-1.19) | 0.574 | |
% | 0.09 (0.06-0.11) | 0.1 (0.04-0.26) | 0.08 (0.06-0.14) | 0.08 (0.07-0.13) | 0.574 | ||
Chrome†† | mcg | 24.86 (4.56-44.43) | 2.85 (1.71-5.7) | 2.28 (0.01-2.85) | 2.28 (0-7.88) | 0.001 | Control >3 |
% | 89.51 (20.1-222.16) | 9.5 (7.2-19) | 11.4 (6.65-39.81) | 11.41 (0.01-30.18) | 0.001 | Control >3 | |
Iron‡ | mg | 6.56 (4.74-8.19) | 5.97 (5.06-6.67) | 7.19 (5.32-9.41) | 5.81 (4.28-10.14) | 0.846 | |
% | 82 (59.22-102.38) | 74.66 (63.22-83.38) | 89.83 (66.44-117.63) | 72.64 (53.48-126.8) | 0.846 | ||
Fluorine‡ | mcg | 0.01 (0-0.03) | 0 (0-0) | 0 (0-0.03) | 0 (0-0.05) | 0.716 | |
% | 0.33 (0.06-0.83) | 0 (0-0) | 0 (0-0.83) | 0.1 (0-1.38) | 0.753 | ||
Folate‡ | mcg | 32.65 (13.9-56.79) | 4.63 (1.35-24.52) | 17.85 (1.35-34.31) | 9.64 (1.5-38.06) | 0.086 | |
% | 8.16 (3.48-14.2) | 1.16 (0.34-6.13) | 4.46 (0.34-8.58) | 2.41 (0.37-9.51) | 0.086 | ||
Phosphor‡ | mg | 721.38 (580.19-850.38) | 727.94 (568.09-826.65) | 929.46 (718.58-1069.6) | 883.83 (710.51-957.26) | 0.088 | |
% | 103.05 (82.88-121.48) | 103.99 (81.16-118.09) | 132.78 (102.65-152.8) | 126.26 (101.5-136.75) | 0.088 | ||
Iodine††† | mcg | 36.48 (6.76-68.31) | 1.11 (0-4.51) | 3.11 (0-12.89) | 16.34 (0-27.87) | 0.104 | |
% | 24.32 (4.51-45.54) | 0.74 (0-3.01) | 4.14 (0-13.81) | 10.9 (0-18.58) | 0.104 | ||
Magnesium‡ | mg | 192.53 (161.83-242.97) | 217.52 (95.72-236.07) | 169.84 (130.86-208.69) | 199.23 (154.52-226.13) | 0.485 | |
% | 56.09 (43.52-75.71) | 55.51 (22.79-64.02) | 44.2 (36.91-65.21) | 51.91 (44.97-63.86) | 0.394 | ||
Manganese‡ | mg | 1.63 (2.14-3.45) | 2 (2.33-2.49) | 1.43 (1.73-3.37) | 1.42 (1.97-2.67) | 0.601 | |
% | 78.91 (110.56-169.58) | 97.75 (101.2-138.33) | 79.24 (91.41-146.3) | 72.77 (103.89-148.47) | 0.498 | ||
Potassium‡ | mg | 1701.34 (1468.07-2097.32) | 2227.85 (1124.25-2321.34) | 1978.62 (1596.58-2395.12) | 1889.39 (1437.28-2294.09) | 0.405 | |
% | 36.2 (31.24-44.62) | 47.4 (23.92-49.39) | 42.1 (33.97-50.96) | 40.2 (30.58-48.81) | 0.405 | ||
Selenium‡ | mg | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0.701 | |
% | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0.701 | ||
Sodium‡ | mcg | 1070.16 (871.89-1465.71) | 1015.84 (662.68-1130.23) | 1381.1 (802.86-1678.84) | 1107.22 (741.05-1469) | 0.801 | |
% | 82.32 (67.07-112.75) | 78.14 (50.98-86.94) | 106.24 (61.76-129.14) | 85.17 (57-113) | 0.801 | ||
Zinc‡ | mcg | 8.6 (6.62-11.9) | 8.36 (6.35-10.65) | 10.32 (8.52-11.58) | 7.38 (6.65-8.84) | 0.323 | |
% | 106.44 (71.22-119.64) | 88.96 (57.7-96.82) | 106.35 (92.5-136.75) | 87.19 (65.05-110.5) | 0.237 |
Data are presented as median (P25-P75). CDR: clinical dementia rating (cases); n; sample number; Kruskall-Waliss (Bonferroni for multiple comparisons). ** There was a statistical difference between elderly control subjects and elderly with moderate dementia (p<0.05). *** There was a statistical difference between elderly control subjects and elderly with mild and advanced dementia (p<0.05). † There was a statistical difference between elderly control subjects and elderly with mild, moderate and advanced dementia (p<0.05). ‡ There was no difference between groups (p>0.05).
Diet and nutritional factors are known modifiable factors for dementia and cognitive decline later in life, with significant associations between an inadequate nutritional status and behavioral disorders with greater impact on activities of daily living12.
The sample was made up mostly of patients with advanced dementia (50% of AD patients), and is similar to the study of Goes et al.7 where 40% of the sample were in the advanced stages of the disease. Advanced disease is characterized by severe memory loss, with no capacity to make decisions, and requires a caregiver or person who can assist in the practice of activities of daily living, and most of them can result in food imbalances and consequent malnutrition.
A high BMI in middle age is associated with an increased risk for the development of dementia7. The elderly studied in the control group, and in the CDR1 and CDR2 groups, were overweight and as the staging of the disease increases, BMI decreases. This overweight condition is likely related to the food preferences found for this group, carbohydrates and lipids. These preferences and dietary deficiencies could be caused by the low family income found in the study, and also due to the decrease in executive functionality and dysphagia3, changing the consumption of proteins for carbohydrates13.
Tieland et al.12, in the Netherlands, analyzed three groups of elderly people, 707 individuals living independently in the community, of which 194 were fragile and 276 were institutionalized. The results showed that 35% of the institutionalized elderly had inadequate protein intake, below 0.7g/kg/day. As protein intake is impaired, there is an accelerated loss of muscle mass, sarcopenia13, low hemoglobin levels, and a consequent increase in the mortality rate14.
According to IBGE research15 held in Brazil, the average consumption of lipids for men and women 60 years or more, is approximately 49 grams. In the present study, the control group had a higher intake, at 42.89 grams, in comparison to CDR 3, 32.24 grams. Diets high in fat contribute significantly in β-amyloid accumulation, tau hyperphosphorylation and an inflammatory state in the peripheral organs and brain16.
Analyzing the thiamine intake (vitamin B1), differences in consumption between groups can be seen. The control group had the lowest intake, likely related to the vitamin supplementation initiated after diagnosis of dementia. Relating IBGE data15, the micronutrient ingestion for elderly is approximately 1.05 mg, while the amount for the AD group was far below.
In the study by Morris et al.17, the total of 3,718 participants aged 65 years and over had dietary data taken, with at least two evaluations and analyzes of cognitive changes over a median of 5.5 years. In this prospective study, nutritional deficiencies of niacin (vitamin B3) were associated with AD and cognitive decline. Since the higher intake of vitamin B3 was associated with a slow rate of cognitive decline and its retardation. The nutritional recommendation for the elderly aged 60 years or more is the intake of approximately 22.7 mg/day7.
There are studies in which the importance of vitamin D is postulated in cases of dementia18,19 as it promotes the regulation of calcium homeostasis, β-amyloid peptide clearance, slows down and/or improves cognitive decline, and has an important antioxidant and anti-inflammatory effect20. In the cohort study conducted by Karakis et al.18, in the USA, the final sample being composed of 1663 patients, vitamin D was associated with lower hippocampal volumes, helping to prevent brain lesions and cognitive decline. The ingestion of calciferol in the related study was impaired in all dementia phases. This may be due to their eating habits. The recommendation according to IBGE15 for individuals over 60 years or more is on average 3.05 mcg/day.
Vitamin E eliminates free radicals, with some chemical forms have a potent anti-inflammatory effect, and the α-tocotrienol congener protects the cortical and hippocampal neurons from apoptosis. Vitamin E deficiency in human manifests primarily as peripheral sensory neuropathy, which demonstrates its essential role in the formation and maintenance of CNS function, supporting its potential use in the prevention and treatment of neurodegenerative diseases21. According to the recommendations of the National Institutes of Health of the United States, the recommended daily dose of vitamin E for an adult is 15mg22. For the IBGE15, 3.8 mg/day is recommended for elderly individuals.
A study in the Netherlands23 involved a sample of 5395 participants over 55 years of age who did not present with dementia. These individuals completed checklists about their eating habits over the past year. The indicated food would have been consumed at least twice a month. Participants were followed for 9.6 years. Of these, 465 developed dementias, of which 365 were diagnosed as having AD. Individuals with vitamin E consumption had a 25% lower risk of developing dementia. It is interesting to analyze the control group of the present study, because it was observed that when comparing the group without AD, all the dementia groups had a lower consumption of this important vitamin.
However, with regard to vitamin K, studies demonstrate the importance of activities related to the brain24,25. It is related to the transport of the apolipoprotein E (ApoE), a major of marker26,27. In the study of Carrié et al.28, conducted with mice to analyze the cognitive ability of a diet low in vitamin K, a vitamin K depleted diet resulted in higher cognitive deficits. In the study by Presse et al.24, a paired control case study of 31 control subjects and with AD, respectively, as in the present study, the healthy group consumed more food containing this vitamin.
The number of works that present calcium as an important underlying factor in the process functional changes of aging, especially in AD has increased29,30. Its dysregulation causes loss of function and mutations in the protein presenilin 1 (PS1), which is a risk factor for the onset of the disease. Other effects include alterations in the autophagic and lysosomal pathways31,32, increased oxidative stress and consequent inflammation in neuronal cells33,34. Patients without neurodegeneration, however, consumed less calcium in their diet compared to those who had moderate dementia, CDR-2 and advanced dementia, CDR-3. The increased intake of dairy products in the diet of survey participants with dementia due to preference from soft textures of the food at this stage of life and stage of disease is the likely cause of this finding.
Among the micronutrients observed in Table 5, we highlight the chromium, which was less consumed by AD patients in CDR-3, as recommended by IBGE17. In the study by Krikorian et al.34, a double-blind study was conducted in Cincinnati, USA, to evaluate whether chromium supplementation helps in memory and neuronal function in the elderly with cognitive decline. The results were that chromium picolinate supplementation may significantly improve cognitive inhibitory control and brain function in individuals who have neurodegeneration.
A cross-sectional study was conducted in Brazil in a group of 135 elderly women with mean age of 68 years, in which 42% of the women analyzed had iodine deficiency35. Iodine deficiency causes thyroid dysfunction, as well as hypertension, dyslipidemia, muscle wasting, frailty and neuromuscular dysfunction, reducing quality and life expectancy36. There is still no daily recommendation for iodine intake specifically for the elderly population.
The sample size and the fact that the values presented being an estimative from the nutritional consumption were the limitations of the study. Therefore, these results are in agreement with similar researches that consider nutritional consumption7.
The nutritional status of an individual is associated with cognitive health and disease progression. According to the results, it is concluded that the progression of dementia is associated with lower levels of dietary intake of some macro and micronutrients. Among the macros, reduced intake of lipids in mild and severe dementia can be observed. Regarding the micronutrients vitamin D intake showed a reduction in mild dementia stage. The vitamins B5, E, and K, and minerals calcium and chromium, had reduced consumption in severe dementia cases. Specific nutritional interventions can alter the development of the disease with low risk of side effects and with satisfactory results particularly in the early stages of the disease.
All raw data was freely available on Open Science Framework site. Dataset 1: Adequacy of food consumption in elderly Alzheimer’s disease in a community of Southern Brazil: a Cross-sectional study. http://doi.org/10.17605/OSF.IO/89USV10
The data is available under a CC0 1.0 license.
The authors would like to thank the Araucaria Foundation, National Council for Scientific and Technological Development (CNPq), Coordination of Improvement of Higher Level Personnel (CAPES) and AEPAPA for providing funding for study.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Alzheimers disease, biomarkers
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
No
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Nutritional, dementia and aging epidemiology
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 29 May 18 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)